Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239032
Licensed Products shall mean and include any and all biological materials and products and processes the making, having made, using, selling or importing of which would, but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents.
Licensee uses advances in biological sciences to discover, develop, manufacture and market products that treat or prevent infectious diseases, immune system disorders and cancer.
IPSCIO Record ID: 239014
Licensed Products shall mean and include any and all protein or peptide based products or biological materials, including antibodies, or other processes and products in the Licensed Field, the making, using, selling or importing of which would, but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents.
patents, commonly known as the CMV promoter patents, or Stinski patents, relating to the expression of recombinant proteins used in the manufacture of Aurexis.
Aurexis is currently being evaluated in a Phase II clinical trial as a first-line therapy, in combination with standard of care antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients.
Staphylococcus aureus is a Gram-positive, round-shaped bacterium that is a member of the Firmicutes, and it is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin.
IPSCIO Record ID: 369338
The rights granted by Licensor to Licensee shall become non-exclusive, at the option of Licensor, if (i) Licensee fails to perform.
Licensor shall retain all right, title, and interest in, to and under the Patent Rights except for the rights explicitly granted to Licensee in accordance with this Agreement.
Licensee shall have the right to sublicense non-exclusively the rights and/or licenses granted by Licensor to Licensee; provided, however, that (i) the sublicensee shall have no further right to grant sublicenses; (ii) the terms of any sublicense shall not be inconsistent with the terms of this Agreement; and (iii) Licensee promptly shall provide Licensor with a copy of each final sublicense agreement within ten (10) days after execution.
US 6,133,433 – Method for detection and prevention of human cytomegalovirus infection
Patent Rights means, collectively, all right, title and interest of Licensor in, to and under (i) United States Patents Nos. 6,242,567, entitled â€œMethod for detection and prevention of human cytomegalovirus infectionâ€ and 6,133,433, entitled â€œMethod for detection and prevention of human cytomegalovirus infection,â€ (ii) all foreign counterparts of United States Patents Nos. 6,242,567 and 6,133,433; and (iii) any continuations-in-part, continuations, continued prosecution applications, divisionals, reexaminations reissues, or patent term extension patents claiming substantially the same technology as United States Patents Nos. 6,242,567 and 6,133,433.
Cytomegalovirus (CMV) is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, in the subfamily Betaherpesvirinae.
Field means all recombinant CMV vaccines containing or encoding molecules larger than fifty (50) amino acids, including DNA-based, viral-based and recombinant protein-based vaccines, and excludes diagnostics.
IPSCIO Record ID: 345562
ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.
IPSCIO Record ID: 110461
Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.
IPSCIO Record ID: 248332
Immune Modulator shall mean Coleys proprietary immunomodulatory oligonucleotide whose confidential sequence has been identified by Licensor as CpG 7909.
Licensed Product shall mean a product labeled for use in the Field and consisting of Immune Modulator, up to a maximum dose of 2 mg per administration, coformulated with one or more Antigens in a single vial; syringe or other suitable container.
VaxImmuneâ„¢ is one member of Coleyâ€™s family of CpG TLR9 agonists, which are short synthetic DNA-like sequences that invoke potent innate and adaptive immune responses of the bodyâ€™s immune system, comprised of both antibody- and cell-mediated pathways. Recent published scientific research by independent researchers have demonstrated that VaxImmuneâ„¢ vaccine adjuvants are suitable for use in both prophylactic and therapeutic vaccines and can elicit a powerful immune response against infectious disease and cancers.
VaxImmune is known as a vaccine adjuvant, used in conjunction with a vaccine to improve immune responses and make the vaccine more effective.